TY - JOUR
T1 - MRI-based radiomics signature for localized prostate cancer
T2 - a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218)
AU - Gugliandolo, Simone Giovanni
AU - Pepa, Matteo
AU - Isaksson, Lars Johannes
AU - Marvaso, Giulia
AU - Raimondi, Sara
AU - Botta, Francesca
AU - Gandini, Sara
AU - Ciardo, Delia
AU - Volpe, Stefania
AU - Riva, Giulia
AU - Rojas, Damari Patricia
AU - Zerini, Dario
AU - Pricolo, Paola
AU - Alessi, Sarah
AU - Petralia, Giuseppe
AU - Summers, Paul Eugene
AU - Mistretta, Frnacesco Alessandro
AU - Luzzago, Stefano
AU - Cattani, Federica
AU - De Cobelli, Ottavio
AU - Cassano, Enrico
AU - Cremonesi, Marta
AU - Bellomi, Massimo
AU - Orecchia, Roberto
AU - Jereczek-Fossa, Barbara Alicja
N1 - Funding Information:
LJI was partially supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), by project IG-13218 “Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion,” registered at ClinicalTrials.gov (NCT01913717), and SGG by project IG-14300 “Carbon ions boost followed by pelvic photon intensity modulated radiotherapy for high-risk prostate cancer,” registered at ClinicalTrials.gov (NCT02672449). MP was supported by a research grant from Accuray Inc. entitled “Data collection and analysis of Tomotherapy and CyberKnife breast clinical studies, breast physics studies and prostate study.” The work was also partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. The sponsors did not play any role in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication. All authors have participated in (a) conception and design, or analysis and interpretation of the data; (b) drafting the article or revising it critically for important intellectual content; and (c) approval of the final version.
Funding Information:
The study was partially funded by Associazione Italiana per la Ricerca sul Cancro (AIRC) and by Accuray Inc. Acknowledgments
Publisher Copyright:
© 2020, European Society of Radiology.
PY - 2021/2
Y1 - 2021/2
N2 - Objectives: Radiomic involves testing the associations of a large number of quantitative imaging features with clinical characteristics. Our aim was to extract a radiomic signature from axial T2-weighted (T2-W) magnetic resonance imaging (MRI) of the whole prostate able to predict oncological and radiological scores in prostate cancer (PCa). Methods: This study included 65 patients with localized PCa treated with radiotherapy (RT) between 2014 and 2018. For each patient, the T2-W MRI images were normalized with the histogram intensity scale standardization method. Features were extracted with the IBEX software. The association of each radiomic feature with risk class, T-stage, Gleason score (GS), extracapsular extension (ECE) score, and Prostate Imaging Reporting and Data System (PI-RADS v2) score was assessed by univariate and multivariate analysis. Results: Forty-nine out of 65 patients were eligible. Among the 1702 features extracted, 3 to 6 features with the highest predictive power were selected for each outcome. This analysis showed that texture features were the most predictive for GS, PI-RADS v2 score, and risk class; intensity features were highly associated with T-stage, ECE score, and risk class, with areas under the receiver operating characteristic curve (ROC AUC) ranging from 0.74 to 0.94. Conclusions: MRI-based radiomics is a promising tool for prediction of PCa characteristics. Although a significant association was found between the selected features and all the mentioned clinical/radiological scores, further validations on larger cohorts are needed before these findings can be applied in the clinical practice. Key Points: • A radiomic model was used to classify PCa aggressiveness. • Radiomic analysis was performed on T2-W magnetic resonance images of the whole prostate gland. • The most predictive features belong to the texture (57%) and intensity (43%) domains.
AB - Objectives: Radiomic involves testing the associations of a large number of quantitative imaging features with clinical characteristics. Our aim was to extract a radiomic signature from axial T2-weighted (T2-W) magnetic resonance imaging (MRI) of the whole prostate able to predict oncological and radiological scores in prostate cancer (PCa). Methods: This study included 65 patients with localized PCa treated with radiotherapy (RT) between 2014 and 2018. For each patient, the T2-W MRI images were normalized with the histogram intensity scale standardization method. Features were extracted with the IBEX software. The association of each radiomic feature with risk class, T-stage, Gleason score (GS), extracapsular extension (ECE) score, and Prostate Imaging Reporting and Data System (PI-RADS v2) score was assessed by univariate and multivariate analysis. Results: Forty-nine out of 65 patients were eligible. Among the 1702 features extracted, 3 to 6 features with the highest predictive power were selected for each outcome. This analysis showed that texture features were the most predictive for GS, PI-RADS v2 score, and risk class; intensity features were highly associated with T-stage, ECE score, and risk class, with areas under the receiver operating characteristic curve (ROC AUC) ranging from 0.74 to 0.94. Conclusions: MRI-based radiomics is a promising tool for prediction of PCa characteristics. Although a significant association was found between the selected features and all the mentioned clinical/radiological scores, further validations on larger cohorts are needed before these findings can be applied in the clinical practice. Key Points: • A radiomic model was used to classify PCa aggressiveness. • Radiomic analysis was performed on T2-W magnetic resonance images of the whole prostate gland. • The most predictive features belong to the texture (57%) and intensity (43%) domains.
KW - Biomarkers
KW - Classification
KW - Magnetic resonance imaging
KW - Prostatic neoplasms
KW - Radiomics
UR - http://www.scopus.com/inward/record.url?scp=85089899537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089899537&partnerID=8YFLogxK
U2 - 10.1007/s00330-020-07105-z
DO - 10.1007/s00330-020-07105-z
M3 - Article
C2 - 32852590
AN - SCOPUS:85089899537
SN - 0938-7994
VL - 31
SP - 716
EP - 728
JO - European Radiology
JF - European Radiology
IS - 2
ER -